Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:COCP

Cocrystal Pharma 5/21/2026 Earnings Report

Cocrystal Pharma logo
$1.44 +0.06 (+4.06%)
As of 11:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cocrystal Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Date
5/21/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cocrystal Pharma Earnings Headlines

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285434/0/en/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-clinical-advancement-of-cdi-988-for-the-prevention-and-treatment-of-norovirus-infection.html
Cocrystal Pharma (COCP) price target increased by 33.33% to 8.16
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cocrystal-pharma-cocp-price-target-increased-by-33-33-to-8-16/ar-AA20VRKV
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 6 at 1:00 AM  |  Profits Run (Ad)
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
April 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-keeping-eye-cocrystal-pharmas-125701156.html
(PMZN) Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
April 3, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/pmzn-cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive-a6c77290
Cocrystal Pharma stock surges on FDA Fast Track designation
April 2, 2026  |  za.investing.comhttps://za.investing.com/news/stock-market-news/cocrystal-pharma-stock-surges-on-fda-fast-track-designation-93CH-4195979
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

View Cocrystal Pharma Profile
Earnings Tools